Clinical Trials Logo

Filter by:
NCT ID: NCT04846634 Not yet recruiting - Clinical trials for Resectable Locally Advanced Non-small Cell Lung Cancer

Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)

ALTER-L043
Start date: August 2021
Phase: Phase 2
Study type: Interventional

This is a multicenter, randomized, open label, phase II study.

NCT ID: NCT04846491 Active, not recruiting - Chronic Hepatitis B Clinical Trials

A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B

Start date: December 4, 2019
Phase: Phase 3
Study type: Interventional

Current clinical practices has shown promising prospects of the therapy strategy of interferon combined with nucleos(t)ides in patients with chronic hepatitis B, but the safety and efficacy has not been fully studied. This study is aimed to exploit the safety and efficacy of the study drug, Peginterferon alfa-2b injection, with nucleos(t)ide (NAs), tenofovir disoproxil fumarate tablets (TDF), in the patients with hepatitis B, who has previously treated with nucleos(t)ides and who are treatment naïve.

NCT ID: NCT04846452 Not yet recruiting - Metastatic NSCLC Clinical Trials

Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC

Start date: May 1, 2021
Phase: Phase 2
Study type: Interventional

This is a single-arm, prospective, exploratory clinical study aiming to evaluate the efficacy and safety profile of sintilimab combined with anlotinib hydrochloride and platinum-containing dual-agent chemotherapy regimens in advanced or metastatic NSCLC as first-line treatment. Totally 40 patients with negative driver genes (20 patients of squamous cell carcinoma, 20 patients of non-squamous cell carcinoma) are to be enrolled.

NCT ID: NCT04846439 Not yet recruiting - Clinical trials for Acute Leukemia in Remission

Sequential Infusion of CD19 and BCMA CAR-T Cells to Improve PTR in Patients With AL

Start date: April 20, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Alloimmune-mediated platelet transfusion refractoriness(PTR) was usually caused by repeated blood transfusions and pregnancy and accounts for about 20-25% of PTR patients. Patients with acute leukemia need repeated platelet infusion in myelosuppression period after chemotherapy, and PTR incidence is more higher.PTR was associated with adverse events,including longer hospital stays,severe hemorrhages and an increased risk of early deaths and may have a negative impact on the success of HSCT. The current management of patients with PTR includes specific transfusion strategies, IVIG, rituximab,thrombopoietin-receptor agonists(TPO-RA) ,bortezomib or splenectomy,have been largely unsatisfactory. As we know, HLA antibodies are mainly secreted by the plasma cells. Researchers want to see if sequential infusion of CD19 and BCMA CAR-T cells can clear the B cells and plasma cells, can help increase platelet levels and reduce bleeding in patients with platelet transfusion refractoriness. To see if sequential infusion can increases platelet levels more after a transfusion. To see if it reduces the chance of bleeding. Adults 16-65 years old who diagnosed with acute leukemia in CR and alloimmune platelet transfusion refractoriness.

NCT ID: NCT04845399 Recruiting - Hemophilia A Clinical Trials

Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A

Start date: April 16, 2021
Phase: Phase 3
Study type: Interventional

The primary objectives of the study are to further evaluate the efficacy and safety of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW107) in adolescent and adult patients with hemophilia A.

NCT ID: NCT04845139 Recruiting - Clinical trials for Primary Central Nervous System Lymphoma

A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma

Start date: April 15, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether Nivolumab given intrathecally is effective in the treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

NCT ID: NCT04844957 Recruiting - Vitamin D Clinical Trials

Clinical Study of the Effect of Vitamin D on the RAAS System in Children With Chronic Orthostatic Intolerance (POTS)

CSOPOTS
Start date: May 20, 2020
Phase: Early Phase 1
Study type: Interventional

chronic orthostatic intolerance in children;postural tachycardia syndrome;vitamin D;RAAS;atecholamines

NCT ID: NCT04844671 Recruiting - Cancer, Lung Clinical Trials

Patients' Expectations About Effects of Robotic Surgery for Cancer

Start date: April 25, 2021
Phase:
Study type: Observational [Patient Registry]

Robotic surgery for common surgical procedures is on the rise despite limited evidence to support its clinical benefit. We intend to to map and characterize the prevalence of the patients'expectation that robotic surgery might be superior to open or laparoscopic procedures and to identify the sociodemographic, clinical and organisational factors associated with this expectation.

NCT ID: NCT04844619 Not yet recruiting - Clinical trials for Neovascular Glaucoma

KDR2-2 Suspension Eyedrop in Treatment of Neovascular Glaucoma (KR-NVG Trial)

KR-NVG
Start date: April 9, 2021
Phase: Early Phase 1
Study type: Interventional

The exploratory clinical trial is aiming at evaluating the effectiveness of neovascularization regression of KDR2-2 topical suspension eyedrop in the treatment of severe neovascular glaucoma. The planned dose levels are 0.96 or 4.8 mg/per day/eye, in a QID fashion, ×7 days (those without complications can continue to 14 days). Subjects are randomized to either 0.96 and 4.8 mg/day/eye in each dosing levels. The overall sample size is 20.

NCT ID: NCT04844385 Recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

Start date: February 20, 2021
Phase: Phase 2
Study type: Interventional

This Phase II randomized study is to determine the efficacy and toxicity of toripalimab plus neoadjuvant chemotherapy combined with chemoradiotherapy for locally advanced unresectable esophageal squamous cell carcinoma.